Article: Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM; (2014) “Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential”, Molecular Diagnosis & Therapy, 18 (4): 389-402
Abstract: Circulating tumor cells (CTCs) have emerged as a viable solution to the lack of tumor tissue availability for patients with a variety of solid tumors, including prostate cancer. Different approaches have been used to capture this tumor cell population and several of these techniques have been used to assess the potential role of CTCs as a biological marker to predict treatment efficacy and clinical outcome. CTCs are now considered a strong tool to understand the molecular characteristics of prostate cancer, and to be used and analyzed as a ‘liquid biopsy’ in the attempt to grasp the biological portrait of the disease in the individual patient.
Funding Acknowledgement: National Cancer Institute (NCI) [CA062948, CA137020, U54 CA143876]; Associazione Italiana per la Ricerca sul Cancro (AIRC); Weill Cornell Clinical and Translational Science Center; Prostate Cancer Foundation; Genitourinary Oncology Research Fund
Funding Text: This work was supported in part by National Cancer Institute (NCI) grants CA062948, CA137020, and U54 CA143876. Luigi Portella was in part supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC). Additional support was received from the Weill Cornell Clinical and Translational Science Center, the Prostate Cancer Foundation, and the Genitourinary Oncology Research Fund. The authors thank Matt Sung for kindly providing the images. The authors have no conflicts of interest that are directly relevant to the content of this article.